Trials / Terminated
TerminatedNCT04258111
IBI310 in Combination with Sintilimab in Patients with DNA Mismatch Repair Deficient (dMMR)/microsatellite Instability High (MSI-H) Locally-advanced or Metastatic Colorectal Cancer
An Open-label, Multicenter, Phase 2 Study of IBI310 in Combination with Sintilimab in Patients with DNA Mismatch Repair Deficient (dMMR) /microsatellite Instability High (MSI-H) Locally-advanced or Metastatic Colorectal Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to assess the efficacy and safety of IBI310 in combination with sintilimab in patients with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) locally advance or metastatic colorectal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | IBI310 (anti-CTLA-4 antibody) | Specified dose on specified days |
| BIOLOGICAL | Sintilimab(anti-PD-1 antibody) | Specified dose on specified days |
Timeline
- Start date
- 2020-08-27
- Primary completion
- 2020-10-26
- Completion
- 2020-10-26
- First posted
- 2020-02-06
- Last updated
- 2024-11-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04258111. Inclusion in this directory is not an endorsement.